相关实验视频
Updated: Jul 7, 2025

07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
12.9K
肌肉心血管氨酸转化酶2蛋白表达在缺血性心力衰竭中
Vitalija Siratavičiūtė1, Dalia Pangonytė1, Lina Utkienė1
1Laboratory of Cardiac Pathology, Institute of Cardiology, Lithuanian University of Health Sciences, 50161 Kaunas, Lithuania.
International journal of molecular sciences
|December 23, 2023
概括
血管酶转化酶2 (ACE2) 表达在心力衰竭中的变化. 在缺血性心力衰竭的进展过程中,心肌细胞ACE2增加,而非心肌细胞ACE2减少.
科学领域:
- 心血管生物学 心血管生物学
- 分子心脏病学分子心脏病学
- 心脏衰竭病理生理学 病理生理学
背景情况:
- 血管新素转化酶2 (ACE2) -血管新素-(1-7) -Mas受体轴对于调节心肌重塑和心力衰竭 (HF) 是至关重要的.
- 目前对心脏中人类ACE2蛋白的膜结合形式的了解有限.
- 了解ACE2细胞局部化对于理解其在HF发育中的作用至关重要.
研究的目的:
- 为了研究左心室不同类型的心肌细胞内ACE2蛋白的表达模式.
- 为了比较非患病的心脏中的ACE2表达与缺血性心力衰竭 (HF) 的各个阶段.
主要方法:
- 对103个左心室心肌组织样本进行定量和半定量免疫组织化学分析.
- 在不同HF阶段 (A,B,C/D) 的心肌细胞和非心肌细胞中评估ACE2免疫染.
- 为整体ACE2表达量化进行非选择性数字图像分析.
主要成果:
- 在A阶段的HF中,心肌细胞ACE2呈现上升趋势,而非心肌细胞ACE2显著下降 (p < 0.001).
- 乙期肝炎呈现心肌细胞ACE2的增加 (p < 0.001) 与稳定的非心肌细胞ACE2水平.
- 阶段C / D HF显示心肌细胞ACE2表达的峰值 (p < 0.001) 和最低的非心肌细胞ACE2水平 (p < 0.001).
结论:
- 在缺血性心力衰竭进展过程中,心肌细胞和非心肌细胞之间的ACE2蛋白表达显著不同.
- 这些ACE2细胞分布的动态变化与HF的左心室重塑有关.
- 对ACE2细胞特异性作用的进一步研究可能为心力衰竭提供新的治疗点.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
94
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
94
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
161
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
161

